2/12
02:23 pm
kpti
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... [Yahoo! Finance]
Medium
Report
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... [Yahoo! Finance]
2/12
07:54 am
kpti
Karyopharm Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
High
Report
Karyopharm Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/12
07:30 am
kpti
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
High
Report
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
2/5
07:30 am
kpti
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
Low
Report
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
2/5
07:00 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Karyopharm Therapeutics (NASDAQ:KPTI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
2/2
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/12
07:00 am
kpti
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Medium
Report
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
1/2
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/17
10:05 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) was given a new $12.00 price target on by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Karyopharm Therapeutics (NASDAQ:KPTI) was given a new $12.00 price target on by analysts at The Goldman Sachs Group, Inc..
12/17
08:44 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/8
07:00 am
kpti
Karyopharm to Participate in Baird's Biotech Discovery Series
Low
Report
Karyopharm to Participate in Baird's Biotech Discovery Series
12/1
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
07:00 am
kpti
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
11/28
11:36 am
kpti
Looking at the Narrative for Karyopharm as Financing and Trial Milestones Shift the Outlook [Yahoo! Finance]
Low
Report
Looking at the Narrative for Karyopharm as Financing and Trial Milestones Shift the Outlook [Yahoo! Finance]